[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639781":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":36,"responsibleParty":40,"collaborators":36,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":36,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":36,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":72,"whyStopped":36,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":36},{"fullName":5,"class":6},"University of California, San Diego","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Gamma EEG-NFB","EXPERIMENTAL","Participants receive real-time gamma EEG neurofeedback targeting frontal gamma coherence (F3 and F4 electrodes, 30-50 Hz) via a CGX wireless 32-electrode headset. Each session includes a 1-minute resting baseline followed by two 15-minute training blocks. Positive reinforcement (images and music) is contingent on meeting an individualized gamma coherence threshold. Sessions are twice weekly for 12 weeks (30 total sessions).",[13],"Behavioral: EEG Neurofeedback",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham EEG-NFB","SHAM_COMPARATOR","Participants undergo identical procedures to the active arm including EEG electrode placement and the same session structure, twice weekly for 12 weeks. However, the feedback displayed is pre-recorded from prior participants and has no relationship to the participant's own brain activity. Participants and outcome assessors are blinded to group assignment.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","EEG Neurofeedback","Gamma EEG neurofeedback delivered via CGX\u002FCognionics wireless headset (FDA cleared for research use). Active arm receives real-time gamma coherence feedback; sham arm receives pre-recorded feedback unrelated to own brain activity.",[9,15],[26],"EEG NFB",[28],{"name":29,"affiliation":5,"role":30},"Fiza Singh, MD","PRINCIPAL_INVESTIGATOR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Autumn Harris Study Coordinator","CONTACT","858-267-2257",null,"fnlab@health.ucsd.edu",{"name":39,"role":34,"phone":35,"phoneExt":36,"email":37},"Jason Holden Lab Manager, PhD",{"type":30,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"Fiza Singh","Associate Professor","100639781","phase-2-confirmatory-trial-of-gamma-neurofeedback-to-improve-working-memory-in-schizophrenia-100639781",false,"NCT07592169","Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia","Confirmatory Efficacy Trial to Confirm the Effects of Gamma EEG-Neurofeedback on Working Memory in Schizophrenia","Inclusion Criteria:\n\n* 1\\. DSM-5 diagnosis of schizophrenia or schizoaffective disorder, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5) 2. Age 18-55 years 3. Clinically stable: no psychiatric hospitalization in the 3 months prior to enrollment 4. No change in antipsychotic medication type or dosage within 4 weeks prior to baseline assessment 5. Ascertained to be clinically and medically stable by a study investigator 6. Does not meet DSM-5 diagnostic criteria for bipolar disorder or current major depressive episode 7. No electroconvulsive therapy (ECT) within 6 months of baseline assessment 8. Able to read and speak English (corrected vision or hearing aids acceptable) 9. Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* 1\\. Self-reported history of seizure disorder 2. Diagnosed with multiple sclerosis 3. History of stroke or major vascular disease, including insulin-dependent diabetes mellitus 4. HIV\u002FAIDS diagnosis 5. Current (not past) major depressive episode 6. Substance use disorder other than nicotine use disorder or caffeine use disorder in the past year 7. Brain cancer (primary or metastatic) 8. Prior head injury involving loss of consciousness 9. Inability to read or speak English 10. Color blindness that interferes with administration of study assessments 11. Neuropsychological or cognitive testing in the past 6 months using the same measures as this study 12. Score on Letter-Number Sequencing greater than 1 standard deviation above the age-normed mean","ALL","18 Years","55 Years",{"count":54,"type":55},104,"ESTIMATED","INTERVENTIONAL",[58],"PHASE2","This study is a confirmatory, double-blind, placebo-controlled randomized clinical trial (RCT) testing whether gamma EEG neurofeedback (EEG-NFB) improves working memory in adults with schizophrenia or schizoaffective disorder. Participants are randomly assigned to receive either active gamma EEG-NFB (real-time feedback of frontal gamma brain activity) or sham EEG-NFB (false pre-recorded feedback), twice weekly for 12 weeks. Working memory (N-back task), brain gamma coherence, and everyday community functioning are assessed at baseline, mid-treatment, end of treatment, and follow-up.",[61,62],"SCHIZOPHRENIA 1 (Disorder)","Schizoaffecitve Disorder",[64,65,66,67,68,69,70,71],"schizophrenia","neurofeedback","EEG","gamma oscillations","working memory","randomized controlled trial","n-back","community functioning","NOT_YET_RECRUITING","2026-05-11",{"date":75,"type":76},"2026-05-18","ACTUAL",{"date":78,"type":55},"2026-06-01",{"date":80,"type":55},"2030-05-31",{"name":5,"class":6}]